Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer's Disease Clinical Diagnosis [Yahoo! Finance]
Quanterix Corporation (QTRX)
US:NASDAQ Investor Relations:
ir.quanterix.com/investor-relations
Company Research
Source: Yahoo! Finance
for neurological disorders, is pleased to announce the clinical launch of ALZpath Dx , an innovative and novel blood test that can be used in the screening, diagnosis, and monitoring of Alzheimer's disease (AD) based on circulating level of pTau217 in the blood. Neurocode is the first laboratory in the United States to make this test available as a Laboratory Developed Test (LDT) for clinical diagnostic use, clinical trials and other research purposes. Neurocode's pioneering assay measures levels of phosphorylated tau at position 217 (pTau217). pTau217 is widely considered to be the leading transformative blood-based biomarker that will enable earlier and more accurate AD diagnosis, better stratification of patients for clinical trials, improved patient care and treatment, and greater diagnostic specificity and sensitivity than other blood-based biomarkers. The test is powered by the Simoa ® (single-molecule assay) technology of Quanterix Corp. "The clinical availability of the AL
Show less
Read more
Impact Snapshot
Event Time:
QTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTRX alerts
High impacting Quanterix Corporation news events
Weekly update
A roundup of the hottest topics
QTRX
News
- Quanterix To Report First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Quanterix To Report First Quarter 2024 Financial ResultsBusiness Wire
- Quanterix Co. (NASDAQ: QTRX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $32.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain [Yahoo! Finance]Yahoo! Finance
- Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure [Yahoo! Finance]Yahoo! Finance
QTRX
Earnings
- 2/29/24 - Miss
QTRX
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form ARS
- 4/15/24 - Form DEF
- QTRX's page on the SEC website